SAB Biotherapeutics, Inc. (SABS) is a publicly traded company in the Unknown sector. Across all available filings, 18 corporate insiders have executed 52 transactions totaling $35.7K, demonstrating a bullish sentiment with $31.3K in net insider flow. The most recent transaction on Feb 3, 2026 involved a transaction of 1,800,000 shares valued at $0.
No significant insider buying has been recorded for SABS in the recent period.
No significant insider selling has been recorded for SABS in the recent period.
Based on recent SEC filings, insider sentiment for SABS is bullish with an Insider Alignment Score of 94/100 and a net flow of $31.3K. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at SAB Biotherapeutics, Inc. (SABS) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 18 insiders are actively trading SABS stock, having executed 52 transactions in the past 90 days. The most active insider is Capital Gp, Llc Sessa (Executive), who has made 1 transactions totaling $3.0M.
Get notified when executives and directors at SABS file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Feb 3, 2026 | Lawrence Bausch Christoph | CHIEF OPERATING OFFICER | Award | 1,800,000 | $N/A | $0 | C-Suite |
| Feb 3, 2026 | J. Reich Samuel | Executive | Award | 4,800,000 | $N/A | $0 | |
| Jan 5, 2026 | Zaccardelli David | Executive | Award | 240,000 | $N/A | $0 | |
| Jan 5, 2026 | Jain Rita | Executive | Award | 240,000 | $N/A | $0 | |
| Dec 11, 2025 | Kropotova Alexandra | Executive | Payment | 988 | $N/A | $0 | |
| Sep 29, 2025 | Gp, Llc Sessa Capital | Executive | Option Exercise | 1,740,000 | $1.75 | $3.0M | Large |
| Sep 29, 2025 | Moin Andrew | Executive | Option Exercise | 1,740,000 | $1.75 | $3.0M | Large |
| Sep 19, 2025 | Kropotova Alexandra | Executive | Payment | 1,977 | $N/A | $0 | |
| Dec 7, 2023 | Joe Sullivan Eddie | Executive | Purchase | 1,740 | $0.88 | $1.5K | |
| Nov 30, 2023 | King Michael | Executive | Purchase | 5,000 | $0.90 | $4.5K | |
| Nov 29, 2023 | J. Reich Samuel | Executive | Purchase | 11,000 | $0.89 | $9.8K | |
| Nov 24, 2023 | K. Ellias Helen | Executive | Option Exercise | 2,857,142 | $N/A | $0 | |
| Nov 24, 2023 | Moin Andrew | Executive | Option Exercise | 4,584,571 | $N/A | $0 | |
| Nov 24, 2023 | Im Gp, Llc Sessa Capital | Executive | Option Exercise | 4,584,571 | $N/A | $0 | |
| Mar 14, 2023 | Kropotova Alexandra | Executive | Award | 275,000 | $N/A | $0 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Exercise(M) | 5 | $6.1M | 75.9% |
Award(A) | 35 | $1.9M | 23.7% |
Purchase(P) | 5 | $33.5K | 0.4% |
Sale(S) | 1 | $2.2K | 0.0% |
Payment(F) | 2 | $0 | 0.0% |
Gift(G) | 1 | $0 | 0.0% |
Other(J) | 3 | $0 | 0.0% |
Insiders at SAB Biotherapeutics, Inc. are accumulating shares at an accelerated pace. With 18 insiders making 52 transactions totaling $33.5K in purchases versus $2.2K in sales, the net buying activity of $31.3K signals strong executive confidence. Capital Gp, Llc Sessa (Executive) leads the buying activity with $3.0M in transactions across all time.